Biotechnology Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter – Corcept Therapeutics (NASDAQ:CORT) Read more
Biotechnology Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada – Scilex Holding (NASDAQ:SCLX) Read more
Biotechnology Innoveren Scientific’s (OTCMKTS: IVRN) 510(k) Submission Sparks A New Hope For Patients Living With Chronic Non-Healing Wounds – Innoveren Scientific (OTC:IVRN) Read more